RU97106773A - CONTRAST MEANS - Google Patents

CONTRAST MEANS

Info

Publication number
RU97106773A
RU97106773A RU97106773/14A RU97106773A RU97106773A RU 97106773 A RU97106773 A RU 97106773A RU 97106773/14 A RU97106773/14 A RU 97106773/14A RU 97106773 A RU97106773 A RU 97106773A RU 97106773 A RU97106773 A RU 97106773A
Authority
RU
Russia
Prior art keywords
coating agent
diagnostic tool
tool according
paragraphs
metal oxide
Prior art date
Application number
RU97106773/14A
Other languages
Russian (ru)
Other versions
RU2147243C1 (en
Inventor
Хьерсти Фальвик Анна
Невестад Анна
Гуннерсен Хельга
Странде Пер
Клавенесс Йо
Якобсен Анна
Original Assignee
Нюкомед Имагинг А/С
Filing date
Publication date
Application filed by Нюкомед Имагинг А/С filed Critical Нюкомед Имагинг А/С
Priority claimed from PCT/GB1994/002097 external-priority patent/WO1996009840A1/en
Publication of RU97106773A publication Critical patent/RU97106773A/en
Application granted granted Critical
Publication of RU2147243C1 publication Critical patent/RU2147243C1/en

Links

Claims (15)

1. Диагностическое средство, содержащее особый композитный материал, причем частицы, сделанные из него, содержат диагностически эффективный, в значительной мере нерастворимый в воде металлооксидный кристаллический материал и полиионный покрывающий агент, где указанные частицы имеют размеры менее 300 нм, указанный кристаллический материал имеет размер кристалла от 1 до 100 нм, массовое отношение указанного кристаллического материала к указанному покрывающему агенту лежит в интервале от 1000:1 до 11:1, и указанный покрывающий агент выбран из группы, содержащей природные и синтетические структурные полисахариды, синтетические полиаминокислоты, физиологически переносимые синтетические полимеры и их производные.1. A diagnostic tool containing a special composite material, wherein the particles made from it contain a diagnostically effective, substantially water-insoluble metal oxide crystalline material and a polyionic coating agent, wherein said particles are less than 300 nm in size, said crystalline material has a crystal size from 1 to 100 nm, the mass ratio of the specified crystalline material to the specified coating agent lies in the range from 1000: 1 to 11: 1, and the specified coating agent is selected from g ppy comprising natural and synthetic structural-type polysaccharides, synthetic polyaminoacids, physiologically tolerable synthetic polymers and derivatives thereof. 2. Диагностическое средство по п. 1, отличающееся тем, что указанный покрывающий агент представляет собой природные или синтетические структурные полисахариды, выбранные из пектинов, полигалактуроновой кислоты, гликозаминогликанов, гепариноидов, целлюлоз и полисахаридов морского происхождения. 2. The diagnostic tool according to claim 1, characterized in that said coating agent is a natural or synthetic structural polysaccharide selected from pectins, polygalacturonic acid, glycosaminoglycans, heparinoids, celluloses and polysaccharides of marine origin. 3. Диагностическое средство по п. 2, отличающееся тем, что указанный покрывающий агент выбран из дерматанов, гепаринов, гепаранов, кератанов, гиалуроновой кислоты, каррагинанов и хитозанов. 3. The diagnostic tool according to claim 2, characterized in that said coating agent is selected from dermatans, heparins, heparanes, keratans, hyaluronic acid, carrageenans and chitosans. 4. Диагностическое средство по п. 2, отличающееся тем, что указанный покрывающий агент представляет собой хондроитин. 4. The diagnostic tool according to claim 2, characterized in that said coating agent is chondroitin. 5. Диагностическое средство по п. 1, отличающееся тем, что указанный покрывающий агент представляет собой гомо- или сополимер аспарагиновой кислоты, глютаминовой кислоты или лизина. 5. The diagnostic tool according to claim 1, characterized in that said coating agent is a homo- or copolymer of aspartic acid, glutamic acid or lysine. 6. Диагностическое средство по любому из пп. 1-5, отличающееся тем, что указанный покрывающий агент имеет молекулярную массу в интервале от 500 до 2000000 Да. 6. Diagnostic tool according to any one of paragraphs. 1-5, characterized in that the said coating agent has a molecular weight in the range from 500 to 2,000,000 Da. 7. Диагностическое средство по любому из пп. 1-6, отличающееся тем, что массовое отношение указанных металлоксидных кристаллов к поверхностно связанному покрывающему агенту составляет по крайней мере 15:1. 7. Diagnostic tool according to any one of paragraphs. 1-6, characterized in that the mass ratio of these metal oxide crystals to a surface-bound coating agent is at least 15: 1. 8. Диагностическое средство по любому из пп. 1-6, отличающееся тем, что массовое отношение указанных металлоксидных кристаллов к поверхностно связанному покрывающему агенту находится в интервале от 500:1 до 20:1. 8. The diagnostic tool according to any one of paragraphs. 1-6, characterized in that the mass ratio of these metal oxide crystals to a surface-bound coating agent is in the range from 500: 1 to 20: 1. 9. Диагностическое средство по любому из пп. 1-6, отличающееся тем, что массовое отношение указанных металлоксидных кристаллов к поверхностно связанному покрывающему агенту находится в интервале от 100:1 до 25:1. 9. The diagnostic tool according to any one of paragraphs. 1-6, characterized in that the mass ratio of these metal oxide crystals to a surface-bound coating agent is in the range from 100: 1 to 25: 1. 10. Диагностическое средство по любому из пп. 1 9, отличающееся тем, что указанные металлоксидные кристаллы проявляют суперпарамагнитные свойства. 10. The diagnostic tool according to any one of paragraphs. 1 to 9, characterized in that the said metal oxide crystals exhibit superparamagnetic properties. 11. Диагностическое средство по любому из п. 10, отличающееся тем, что указанные суперпарамагнитные кристаллы представляют собой железооксидные кристаллы. 11. Diagnostic tool according to any one of p. 10, characterized in that the said superparamagnetic crystals are iron oxide crystals. 12. Диагностическое средство по любому из пп. 1-11, отличающееся тем, что указанные частицы обладают дзетапотенциалом, который составляет менее, чем -10 мВ, или более, чем +10 мВ. 12. The diagnostic tool according to any one of paragraphs. 1-11, characterized in that these particles have a zetapotential that is less than -10 mV, or more than +10 mV. 13. Диагностическая композиция, содержащая диагностическое средство по любому из пп. 1-12 и по крайней мере один физиологически переносимый носитель или разбавитель. 13. A diagnostic composition comprising a diagnostic tool according to any one of paragraphs. 1-12 and at least one physiologically tolerable carrier or diluent. 14. Способ получения диагностического средства по п. 1, отличающееся тем, что указанный способ включает (а) соосаждение при значениях рН выше 9 кристаллов диагностически эффективного в значительной мере нерастворимого оксида металла размером от 1 до 100 нм и покрывающего агента или (б) покрытие кристаллов диагностически эффективного в значительной мере нерастворимого оксида металла размером от 1 до 100 нм покрывающим агентом, посредством чего можно получить композитную частицу, имеющую в размере менее 300 нм, массовое отношение кристалла к поверхностно связанному покрывающему агенту находится в интервале от 1000:1 до 11:1, причем указанный покрывающий агент выбран из группы, содержащей природные и синтетические структурные полисахариды и их производные, синтетические полиаминокислоты, физиологически переносимые синтетические полимеры. 14. A method for producing a diagnostic agent according to claim 1, characterized in that said method comprises (a) coprecipitation at pH values above 9 crystals of a diagnostically effective substantially insoluble metal oxide ranging in size from 1 to 100 nm and a coating agent; or (b) coating crystals of a diagnostically effective substantially insoluble metal oxide of 1 to 100 nm in size with a coating agent, whereby it is possible to obtain a composite particle having a size of less than 300 nm, the mass ratio of the crystal to the hnostno bound coating agent is in the range from 1000: 1 to 11: 1, said coating agent being selected from the group consisting of natural and synthetic structural-type polysaccharides and derivatives thereof, synthetic polyaminoacids, physiologically tolerable synthetic polymers. 15. Способ получения контрастно усиленного изображения организма человека или других животных, отличающееся тем, что указанный способ включает введение в указанный организм суспензии контрастного средства по любому из пп. 1-13 с получением изображения, по крайней мере, части указанного организма, в котором распределено указанное средство. 15. A method of obtaining a contrast-enhanced image of the human body or other animals, characterized in that the said method comprises introducing into the specified organism a suspension of a contrast agent according to any one of claims. 1-13 with obtaining an image of at least part of the specified organism in which the specified tool is distributed.
RU97106773A 1994-09-27 1994-09-27 Contrast agent RU2147243C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB1994/002097 WO1996009840A1 (en) 1994-09-27 1994-09-27 Contrast agent
US09/243,437 US6207134B1 (en) 1994-09-27 1999-02-03 Ultrafine lightly coated superparamagnetic particles for MRI

Publications (2)

Publication Number Publication Date
RU97106773A true RU97106773A (en) 1999-05-10
RU2147243C1 RU2147243C1 (en) 2000-04-10

Family

ID=26304264

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97106773A RU2147243C1 (en) 1994-09-27 1994-09-27 Contrast agent

Country Status (11)

Country Link
US (1) US6207134B1 (en)
EP (1) EP0783325B2 (en)
JP (1) JPH10506121A (en)
AT (1) ATE187079T1 (en)
AU (1) AU687093B2 (en)
DE (1) DE69421943T2 (en)
DK (1) DK0783325T3 (en)
ES (1) ES2139097T3 (en)
NO (1) NO971436L (en)
RU (1) RU2147243C1 (en)
WO (1) WO1996009840A1 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT81498B (en) * 1984-11-23 1987-12-30 Schering Ag METHOD FOR PREPARING COMPOSITIONS FOR DIAGNOSTICS CONTAINING MAGNETIC PARTICLES
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
ATE291439T1 (en) 1996-01-10 2005-04-15 Amersham Health As CONTRAST AGENTS
DE19612001A1 (en) * 1996-03-18 1997-09-25 Silica Gel Gmbh Adsorptions Te Superparamagnetic particles with increased R¶1¶ relaxivity, process for their production and their use
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
JP3662347B2 (en) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 Medical powder
NZ333962A (en) * 1996-08-05 2000-07-28 Schering Ag Process and device for the production of contrast media for magnetic resonance tomography
DE19721947C2 (en) * 1997-05-21 1999-04-22 Diagnostikforschung Inst Use of pharmaceutical preparations containing particles, vesicles or polymers as well as non-steroidal anti-inflammatory drugs and / or platelet aggregation inhibitors for the visualization of the vessels, lymph nodes and bone marrow
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
WO2000061191A2 (en) 1999-04-09 2000-10-19 Advanced Magnetics, Inc. Heat stable coated colloidal iron oxides
EP1522318A3 (en) * 1999-04-09 2005-07-06 Advanced Magnetics Incorporated Heat stable coated colloidal iron oxides
AU2001253041A1 (en) * 2000-03-31 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Dendrimer composition for magnetic resonance analysis
US20020034537A1 (en) * 2000-05-03 2002-03-21 Brita Schulze Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20040167244A1 (en) * 2000-08-18 2004-08-26 Auge Wayne K. Methods and compositions for fusing bone during endoscopy procedures
US7445619B2 (en) * 2000-08-18 2008-11-04 Map Technologies Llc Devices for electrosurgery
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6549798B2 (en) 2001-02-07 2003-04-15 Epix Medical, Inc. Magnetic resonance angiography data
DE10108857A1 (en) * 2001-02-14 2002-09-19 Hans-Dieter Hunger Bioactive and biocompatible conjugates with magnetic properties and process for their preparation
US7066932B1 (en) * 2001-05-26 2006-06-27 Map Technologies Llc Biologically enhanced irrigants
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US8734441B2 (en) * 2001-08-15 2014-05-27 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
US8235979B2 (en) * 2001-08-15 2012-08-07 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
US8591508B2 (en) * 2001-08-15 2013-11-26 Nuortho Surgical, Inc. Electrosurgical plenum
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) * 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20040143180A1 (en) * 2001-11-27 2004-07-22 Sheng-Ping Zhong Medical devices visible under magnetic resonance imaging
US20030100830A1 (en) 2001-11-27 2003-05-29 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US7163655B2 (en) * 2002-03-28 2007-01-16 Scimed Life Systems, Inc. Method and apparatus for extruding polymers employing microwave energy
WO2003082547A1 (en) * 2002-03-28 2003-10-09 Scimed Life Systems, Inc. Polymer welding using ferromagnetic particles
US6979420B2 (en) * 2002-03-28 2005-12-27 Scimed Life Systems, Inc. Method of molding balloon catheters employing microwave energy
US6962685B2 (en) * 2002-04-17 2005-11-08 International Business Machines Corporation Synthesis of magnetite nanoparticles and the process of forming Fe-based nanomaterials
US8862203B2 (en) * 2003-03-27 2014-10-14 Boston Scientific Scimed Inc. Medical device with temperature modulator for use in magnetic resonance imaging
US20050240100A1 (en) * 2003-04-08 2005-10-27 Xingwu Wang MRI imageable medical device
US20050278020A1 (en) * 2003-04-08 2005-12-15 Xingwu Wang Medical device
US20050261763A1 (en) * 2003-04-08 2005-11-24 Xingwu Wang Medical device
US20050244337A1 (en) * 2003-04-08 2005-11-03 Xingwu Wang Medical device with a marker
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
US20050014851A1 (en) * 2003-07-18 2005-01-20 Eastman Kodak Company Colloidal core-shell assemblies and methods of preparation
US20070031339A1 (en) * 2003-11-28 2007-02-08 Oskar Axelsson Contrast agents
WO2005063304A2 (en) * 2003-12-24 2005-07-14 Board Of Regents, The University Of Texas_System Poly (l-glutamic acid) paramagnetic material complex and use as a biodegradable mri contrast agent
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
US7761138B2 (en) * 2004-03-12 2010-07-20 Boston Scientific Scimed, Inc. MRI and X-ray visualization
US7483732B2 (en) * 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
DE102004052533A1 (en) * 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Particles for use in diagnosis and therapy, especially for binding therapeutic agent for treating e.g. tumors and bacterial, rheumatic, neurologic and thrombotic diseases, have nanocrystalline magnetic core and envelope enclosing core
DE102004054536A1 (en) * 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal modified cells as cellular dosage forms for active substances and as diagnostic cell particles
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
US20060293396A1 (en) * 2005-01-14 2006-12-28 Eastman Kodak Company Amine polymer-modified nanoparticulate carriers
CN101203249A (en) * 2005-04-01 2008-06-18 德克萨斯大学体系董事会 Poly(peptide) as a chelator: methods of manufacture and uses
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20070237821A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Nanogel-based contrast agents for optical molecular imaging
EP1738773A1 (en) * 2005-06-29 2007-01-03 Schering AG Composition comprising magnetic iron oxide particles and use thereof in medical imaging
US7778684B2 (en) * 2005-08-08 2010-08-17 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20080095699A1 (en) * 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
DE102005053618A1 (en) * 2005-11-10 2007-05-16 Merck Patent Gmbh Nanoscale particles as contrast agent for magnetic resonance imaging
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
DOP2007000020A (en) 2006-01-31 2007-09-15 Bayer Schering Pharma Ag MODULATION OF THE ACTIVITY OF MDL-1 FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20070239256A1 (en) * 2006-03-22 2007-10-11 Jan Weber Medical devices having electrical circuits with multilayer regions
US20070258907A1 (en) * 2006-04-24 2007-11-08 Davis Mark E Polymer-coated paramagnetic particles
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
US7892520B2 (en) * 2006-07-31 2011-02-22 The Hong Kong University Of Science And Technology Solid-state synthesis of iron oxide nanoparticles
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
GB0820309D0 (en) * 2008-11-06 2008-12-17 Middlesex University Higher Ed Detection of cancer
US8574549B2 (en) * 2008-12-29 2013-11-05 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
CN101474414B (en) * 2009-02-06 2010-09-15 上海师范大学 Preparation and application of polymer-coated magnetic nanoparticle contrast agent
US9532827B2 (en) 2009-06-17 2017-01-03 Nuortho Surgical Inc. Connection of a bipolar electrosurgical hand piece to a monopolar output of an electrosurgical generator
US9408658B2 (en) 2011-02-24 2016-08-09 Nuortho Surgical, Inc. System and method for a physiochemical scalpel to eliminate biologic tissue over-resection and induce tissue healing
RU2453270C1 (en) * 2011-03-31 2012-06-20 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" (ФГУ "МНИОИ им. П.А. Герцена" Минздравсоцразвития России) Method of examining terminal part of large intestine
KR101398214B1 (en) * 2011-04-06 2014-05-23 주식회사 바이오리더스 Sensitive MRI Contrast Nano Agents Based Ionic Complex Containing Anionic and Cationic Polymer and Preparing Method Thereof
RU2465010C1 (en) * 2011-06-08 2012-10-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Contrast agent for magnetic resonance tomography
JP6174603B2 (en) * 2012-01-27 2017-08-02 ソルシオネス ナノテクノロジカス，エス．エル．Ｓｏｌｕｃｉｏｎｅｓ Ｎａｎｏｔｅｃｎｏｌｏｇｉｃａｓ，Ｓ．Ｌ． Contrast agent for T2 * -weighted magnetic resonance imaging (MRI)
CZ2012842A3 (en) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. C6-C18-acylated hyaluronate-based nanomicellar composition, process for preparing C6-C18-acylated hyaluronate, process for preparing nanomicellar composition and stabilized nanomicellar composition as well as use thereof
US9579142B1 (en) 2012-12-13 2017-02-28 Nuortho Surgical Inc. Multi-function RF-probe with dual electrode positioning
SG11201507287SA (en) 2013-03-15 2015-10-29 Univ California Peptides having reduced toxicity that stimulate cholesterol efflux
CZ305153B6 (en) 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Conjugates of hyaluronic acid oligomer or a salt thereof, process for their preparation and use
US9597418B2 (en) * 2014-03-18 2017-03-21 Universite De Nantes Magnetic and fluorescent reverse nanoassemblies
CZ2014451A3 (en) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, process of its preparation and use
CZ309295B6 (en) 2015-03-09 2022-08-10 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of its preparation and use
CZ306479B6 (en) 2015-06-15 2017-02-08 Contipro A.S. A method of crosslinking polysaccharides by using photolabile protecting groups
CZ306662B6 (en) 2015-06-26 2017-04-26 Contipro A.S. Sulphated polysaccharides derivatives, the method of their preparation, the method of their modification and the use
JP6879670B2 (en) * 2016-03-30 2021-06-02 小林製薬株式会社 Topical composition for concealing wrinkles and / or pores
CZ308106B6 (en) 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
EP3412303A1 (en) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
WO2020053204A1 (en) 2018-09-10 2020-03-19 Saving Patients' Lives Medical B.V. Ultra-small superparamagnetic iron oxide nanoparticles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5746999A (en) * 1984-11-23 1998-05-05 Schering Aktiengesellschaft Magnetic particles for diagnostic purposes
US5597531A (en) † 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US5262176A (en) † 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US4827945A (en) † 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
WO1990015666A1 (en) † 1989-06-16 1990-12-27 Omni Quest Corporation Coated magnetic particles for use in separations
JP2726520B2 (en) * 1989-10-20 1998-03-11 名糖産業株式会社 Organic magnetic composite
EP0693288B1 (en) * 1990-04-10 1999-10-13 Imarx Pharmaceutical Corp. Polymers as contrast media for magnetic resonance
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
DE4117782C2 (en) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanocrystalline magnetic iron oxide particles, processes for their production and diagnostic and / or therapeutic agents
AU652060C (en) * 1991-06-11 2004-04-22 Meito Sangyo Kabushiki Kaisha Oxidized composite comprising water-soluble carboxypolysaccharide and magnetic iron oxide
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
EP0580878B1 (en) * 1992-06-01 1996-01-10 BASF Aktiengesellschaft The use of dispersions of magneto-ionic particles as MRI contrast media
DK0656368T4 (en) * 1992-08-05 2003-09-29 Meito Sangyo Kk Small diameter composite material containing a water-soluble carboxypolysaccharide and magnetic iron oxide
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles

Similar Documents

Publication Publication Date Title
RU97106773A (en) CONTRAST MEANS
Jayakumar et al. Novel carboxymethyl derivatives of chitin and chitosan materials and their biomedical applications
DE69527307T2 (en) POROUS FINE PARTICLES AND COSMETICS
DE69229358T2 (en) Compositions for enhancing image contrast in the diagnosis of the gastrointestinal tract
DE69507339T2 (en) POLYMER MICROBALLS AND METHOD FOR THE PRODUCTION THEREOF
US4985233A (en) A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier
DK167998B1 (en) DIAGNOSTIC AGENTS CONTAINING A NON-RADIOACTIVE METAL SPECIES CHEMICAL BOND TO MACROMOLECULAR COMPOUNDS AND USING THESE COMPOUNDS WITH THE BOND METAL SPECIES FOR THE PREPARATION OF AN AGENT FOR USE IN USE
EP3740188A1 (en) Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
Raghavan et al. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting
US20040010864A1 (en) Method for treating human keratin fibers with organomodified metallic particles
DE60109036T2 (en) Absorbent articles for women with gel-forming polysaccharide-containing wings
JP4162265B2 (en) Crosslinked copolymer based on polycarboxylic acid polymer
Ignjatović et al. Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling
DE19916896A1 (en) Particles for chelating metal ions, useful in cosmetic, pharmaceutical and food products and products for treating liquids, especially water
AU1262995A (en) Metal-ion chelates with acidic saccharides and glycosaminoglycans
EP1126881B1 (en) Muco-adhesive polymers, use thereof and method for producing the same
CA2045425A1 (en) Powdered superabsorbents, containing silica, their preparation process and their use
EP0714914A1 (en) Swellable starch ester, process for its preparation and its use
CA2265465A1 (en) Aqueous solution compositions comprising polymer hydrogel compositions
AU2004303599B2 (en) Compositions of semi-interpenetrating polymer network
KR20140080467A (en) Polymer Nano Particle Containing UV Blocking Material and Method of Preparing the Same
JP5728739B2 (en) Method for producing moisturizing particles
DE69120700T2 (en) Pair of polypeptides
Fouda Use of natural polysaccharides in medical textile applications
WO2000012589A1 (en) Method for the production of small spherical particles containing at least one water-insoluble linear polysaccharide